Delpharm has increased its capacity by acquiring and installing a new sterile filling line that is fully compliant with Annex 1. Delpharm Saint-Rémy is thus significantly increasing its production capacity for sterile vials and freeze-drying, with an additional 45 million units in the 2 ml format.

This investment, which includes the construction of a new building, is valued at €37 million and benefits from €10.4 million in aid from the French government. This overall investment facilitated the construction of an additional 1,000 m² production area, which was designed to accommodate the new production line, with a capacity to fill vials from 2 ml to 100 ml at a rate of 24,000 vials per hour for the 2 ml format.

The Saint-Rémy site manufactures 16 million boxes and generates annual sales of €38 million. It specializes in sterile liquid dosage forms and freeze-drying. Delpharm Saint-Rémy exports its products worldwide, to Europe, Brazil, and Russia.

In recent years, Delpharm has actively participated in the manufacturing of the BioNTechPfizer vaccine at its Saint-Rémy site, the production of cisatracurium for hospitals at its Dijon site, the rescue of the Mouvaux infusion bag manufacturing site (formerly Carelide), and the securing of corticosteroid production at its Lille site.

Delpharm currently has 18 manufacturing sites and three development centers, located in France, Italy, Canada, the Netherlands, and Poland, producing more than one billion boxes of medication annually and participating in the development of numerous projects.

The company employs more than 6,500 people and generated revenues of €1.1 billion in 2024.